Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Aug;116(2 Pt 1):275-283.
doi: 10.1097/AOG.0b013e3181e79440.

Ovarian suppression in normal-weight and obese women during oral contraceptive use: a randomized controlled trial

Carolyn L Westhoff  1 , Anupama H Torgal, Elizabeth R Mayeda, Frank Z Stanczyk, Jodi P Lerner, Emma K T Benn, Myunghee Paik
Affiliations
Randomized Controlled Trial

Ovarian suppression in normal-weight and obese women during oral contraceptive use: a randomized controlled trial

Carolyn L Westhoff et al. Obstet Gynecol. 2010 Aug.

Abstract

Objective: To assess ovarian suppression during oral contraceptive pill (OCP) use among normal-weight and obese women using two OCP doses.

Methods: This was a prospective, double-blind, randomized trial of two 21-day monophasic OCP formulations (20-microgram ethinyl estradiol [E2],/100-microgram levonorgestrel compared with 30-microgram ethinyl E2/150-microgram levonorgestrel) among normal-weight (body mass index 19.0-24.9) and obese (body mass index 30.0-39.9) women with regular menses and normal ovarian ultrasonography. Participants underwent transvaginal ultrasonography and phlebotomy twice weekly for 4 weeks during the third or fourth OCP cycle. We assessed OCP compliance using serum levonorgestrel levels. Outcomes included follicular development, endogenous E2 levels, ovulation, and self-reported bleeding patterns.

Results: Two hundred twenty-six women enrolled. One hundred eighty-one participants completed the study; we retained 150 consistent OCP users in the main analysis (96 normal weight, 54 obese). Consistent users of either OCP dose had substantial suppression of follicular development; obesity and follicular development were not related. Among the consistent OCP users, 2.7% ovulated during the study cycle (3 of 96 normal-weight and 1 of 54 obese participants). Two ovulations occurred with each OCP formulation. Inconsistent OCP use or nonuse during the study cycle was associated with more ovulation (P<.001). Normal-weight and obese participants had similar follicular development, endogenous estradiol levels, Hoogland scores, and bleeding patterns.

Conclusion: Normal-weight and obese participants who were consistent OCP users experienced substantial and comparable ovarian suppression during OCP use. Higher OCP failure rates among obese women reported elsewhere are thus unlikely to be attributable to physiological differences in OCP effect.

Clinical trial registration: ClinicalTrials.gov, www.clinicaltrials.gov; NCT00827632.

Level of evidence: : I.

PubMed Disclaimer

References

    1. Chandra A, Martinez GM, Mosher WD, Abma JC, Jones J. Fertility, family planning, and reproductive health of U.S. women: data from the 2002 National Survey of Family Growth. Vital Health Stat 23 2005:1–160.
    1. Trussell J. Contraceptive failure in the United States. Contraception 2004;70:89–96.
    1. Dinger JC, Cronin M, Mohner S, Schellschmidt I, Minh TD, Westhoff C. Oral contraceptive effectiveness according to body mass index, weight, age, and other factors. Am J Obstet Gynecol 2009;201:263.e1–9.
    1. McDowell MA, Fryar CD, Ogden CL, Flegal KM. Anthropometric reference data for children and adults: United States, 2003–2006. National health statistics reports; no 10. Hyattsville (MD): National Center for Health Statistics; 2008.
    1. Holt VL, Cushing-Haugen KL, Daling JR. Body weight and risk of oral contraceptive failure. Obstet Gynecol 2002;99:820–7.

Publication types

Associated data